Bivision Pharmaceuticals, Inc. (Bivision) today announced receiving the approval (CXHL2300514)

April 3, 2023 Bivision Pharmaceuticals (hereinafter referred to as "Bivision")

May 15, 2023 Bivision Pharmaceuticals(Shanghai),Inc.(hereinafter referred to as "Bivision”), a biopharmaceutical company focused on discovery , development and commercialization of novel theranostic medicine

Bivision Pharmaceuticals(Shanghai),Inc. (hereinafter referred to as "Bivision") recently announced that its independently developed novel targeted radiopharmaceutical has successfully completed the first patient dosing in Phase I clinical trial. The trial aims to evaluate the safety, pharmacokinetics, and anti-tumor activity in patients with advanced prostate cancer.

In 2021, Bivision Pharmaceuticals (hereinafter referred to as "Bivision") was co-founded by Dr.Haihua Yu, Dr.Yu Wang and other two biotech veterans. Dr.Haihua Yu worked in GSK for more than 10 years in new drug research and development.